Alvotech Ordinary Shares ALVO 深 沪
已收盘 12-19 16:00:00 美东时间
4.91
+0.180
+3.81%
华盛通- 最 高5.85
- 今 开4.80
- 成交量 50.85万股
- 最 低 4.32
- 昨 收 4.73
- 总市值 12.28亿
- 52周最高 13.70
- 市盈率 静 38.42
- 换手率 0.20%
- 52周最低 4.32
- 委 比 -14.45%
- 总股本 2.50亿
- 历史最高 18.00
- 量 比 0.77
- 振 幅 32.35%
- 历史最低 1.10
- 每 手 1
- 风险率 2.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alvotech Wins EU Green Light For Cancer-Related Bone Treatment Alternative
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Commission (EC) has approved AVT03 as a
11-24 18:31
Gold Edges Higher; ISM Manufacturing PMI Falls In October
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index fa...
11-04 03:23
Alvotech Shares Plunge 33% After FDA Flags Issues
Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 revenue and EBITDA outlook.
11-04 02:17
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
11-03 21:14
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
Alvotech and Advanz Pharma announced that the European Medicines Agency (EMA) has recommended approval for Alvotech's biosimilar AVT06 to Eylea® 2 mg, a treatment for eye disorders. This positive opinion brings the product closer to approval in Europe, improving access for patients. AVT06 is designed for conditions like age-related macular degeneration, macular edema, and diabetic macular edema.
06-23 08:00
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
Alvotech completed a private placement on June 4, 2025, attracting around 40 institutional investors, with 60% from Sweden, Norway, or the UK, and 30% from US funds. Over 80% of the shares and SDRs were sold to new shareholders, enhancing Alvotech’s shareholder base and SDR free float. CEO Róbert Wessman welcomed the new investors, emphasizing the company’s journey to lead the biosimilars industry.
06-11 20:18
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Alvotech and Dr. Reddy’s have entered into a collaboration to develop, manufacture, and commercialize a biosimilar to Keytruda (pembrolizumab) for global markets, leveraging their expertise to accelerate development and expand reach.
06-05 06:55
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
Alvotech完成7.5亿瑞典克朗的股票发行，用于研发扩展和市场机会，进一步 diversifying 股东结构，包括瑞典和 intl investors. 输出：Alvotech completed a private placement raising SEK 750 million to expand R&D and seize growth opportunities, diversifying its shareholder base with strong interest from Swedish and international investors.
06-04 23:55
Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares
Alvotech announces its intention to carry out a private placement of approximately 7.5 million Swedish Depository Receipts and ordinary shares, targeting Swedish and international institutional investors. The placement is aimed at broadening the company's shareholder base and financing R&D activities.
06-04 15:32
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
Alvotech completed the acquisition of Xbrane's R&D organization and the biosimilar candidate to Cimzia® for approximately $28.9 million, expanding its development capacity and strengthening its presence in the Swedish biopharma sector.
06-04 11:45
